Abstract:Macrophages are important effector cells in inflammatory responses. They are involved in bacterial infections and autoimmune diseases but also in the low grade inflammation associated with obesity and metabolic syndrome. Macrophages also have homeostatic functions and they activate healing process associated with inflammation and tissue injury [1-3]. To achieve these multiform tasks, macrophages are programmed to display distinct phenotypes in response to environmental signals [2-5]. For example, Th1 cytokine interferon γ (IFNγ) and toll-like receptor 4 (TLR4) ligand lipopolysaccharide (LPS) trigger classical, i.e. type M1, activation of macrophages, which is typical for bacterial infections and autoimmune reactions [6]. On the other hand, Th2 cytokines interleukin (IL) 4 and 13 trigger alternative, i.e. type M2, activation, which is associated with wound healing but also with the aberrant immune responses associated with overactivation of fibroblasts and subsequent fibrosis [6,7]. Classical activation of macrophages leads to the release of proinflammatory and antimicrobial factors including IL-6, IL-12, tumour necrosis factor (TNF) and nitric oxide (NO) produced by inducible nitric oxide synthase (iNOS) pathway. On the other hand, alternatively activated macrophages express factors that have been associated with recognition of extracellular pathogens and/or stimulation of fibroblasts. Some of Abstract: Peroxisome proliferator-activated receptor (PPAR) agonists, fibrates and thiazolidinediones, are commonly used drugs in the treatment of dyslipidemia and diabetes. Their targets, PPARα and PPARγ, have also been shown to have a role in the regulation of inflammatory responses linking metabolism and inflammation. In the present study we investigated the effects of PPAR agonists on macrophage activation. In addition to the proinflammatory classical activation, we also focused on interleukin (IL) 4 and 13 -induced alternative activation which is a significant macrophage phenotype in tissue repairing processes and in fibrosing diseases. PPARα agonists GW7647 and fenofibrate as well as PPARγ agonist GW1929 inhibited lipopolysaccharide-induced classical macrophage activation and production of the characteristic biomarkers of this phenotype, i.e. IL-6 and nitric oxide, in murine J774 macrophages. Remarkably, the PPARα agonists also inhibited IL-4 and IL-13 –induced expression of alternative activation markers arginase-1, fizz1 and mannose receptor 1 whereas the PPARγ agonist GW1929 enhanced their expression in J774 macrophages. The PPARα agonists GW7647 and fenofibrate also attenuated the production of alternative activation markers chemokine (C-C motif) ligand 13 and plateletderived growth factor in human THP-1 macrophages. The present findings show that PPARα and PPARγ agonists differently regulate classical and alternative macrophage phenotypes. Furthermore, PPARα activation was introduced as a novel concept to down-regulate alternative macrophage activation indicating that PPARα agonists have therapeutic potential in conditions associated with Research Article Open Access

Selective inhibition and augmentation of alternative macrophage activation by progesterone

Progesterone inhibits Toll-like receptor 4-mediated innate immune response in macrophages by suppressing NF-κB activation and enhancing SOCS1 expression

miR-155 mediates suppressive effect of progesterone on TLR3, TLR4-triggered immune response

Progesterone Impairs Antigen-Non-specific Immune Protection by CD8 T Memory Cells Via Interferon-Γ Gene Hypermethylation

Effects of Progesterone on the Expression of TNF-α,IL-1β,TLR4,CD14 and MD2 in Mouse Peritoneal Macrophages

Progesterone Attenuates Brain Inflammatory Response and Inflammation-Induced Increase in Immature Myeloid Cells in a Mouse Model

Inhalation of Progesterone Inhibits Chronic Airway Inflammation of Mice Exposed to Ozone

Modulators of the Balance between M1 and M2 Macrophages during Pregnancy

Progesterone-mediated remodeling of the maternal-fetal interface by a PGRMC1-dependent mechanism

Two Antiatherogenic Effects of Progesterone on Human Macrophages; Inhibition of Cholesteryl Ester Synthesis and Block of Its Enhancement by Glucocorticoids.

High concentrations of progesterone inhibit the expression of genes related to steroid metabolism in MA-10 Leydig cells

Abstract 3971: Progesterone impacts regulatory T cell activity to promote immunosuppression in the mammary gland

Activation of Peroxisome Proliferator-activated Receptor γ (PPARγ) and CD36 Protein Expression: THE DUAL PATHOPHYSIOLOGICAL ROLES OF PROGESTERONE

Abstract 5364: Progesterone receptor modulates the antigen processing and presentation machinery decreasing MHC class I expression on tumors

Progesterone Regulates Mouse Dendritic Cells Differentiation and Maturation

17β-Estradiol Promotes TLR4-Triggered Proinflammatory Mediator Production through Direct Estrogen Receptor α Signaling in Macrophages In Vivo

Anti-Inflammatory Effects of Progesterone in Lipopolysaccharide-Stimulated BV-2 Microglia

Anti-inflammatory effects of progesterone through NF-κB and MAPK pathway in lipopolysaccharide- or Escherichia coli-stimulated bovine endometrial stromal cells.

Peroxisome proliferator-activated receptor alpha and gamma agonists differently regulate classical and alternative macrophage activation

Hypothalamic Effects of Progesterone on Regulation of the Pulsatile and Surge Release of Luteinising Hormone in Female Rats

Progesterone Receptor Signaling Selectively Modulates Cytokine-Induced Global Gene Expression in Human Cervical Stromal Cells